Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Prospective, Open-label, Multicentre Phase-II-trial to Evaluate the Efficacy and Safety of a Fitness-adapted Therapy Approach With Either Continuous Zanubrutinib (BGB-3111) Monotherapy or Time-limited Zanubrutinib + Sonrotoclax (BGB-11417) in Older (Aged ≥80 Years) and/or Frail Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL)

Authors not listed

German CLL Study Group · 2026

Abstract

The CLL-Frail2 trial will be a prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a fitness-adapted therapy approach with either con-tinuous zanubrutinib (BGB-3111) monotherapy or time-limited zanubrutinib + sonrotoclax (BGB-11417) in older (aged ≥80 years) and/or frail patients with treatment-naïve CLL. The primary objective of the study is to evaluate the efficacy and safety of fitness-adapted therapy in older (aged ≥80 years) and/or frail patients with treatment-naïve CLL.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Anonymous. (2026). A Prospective, Open-label, Multicentre Phase-II-trial to Evaluate the Efficacy and Safety of a Fitness-adapted Therapy Approach With Either Continuous Zanubrutinib (BGB-3111) Monotherapy or Time-limited Zanubrutinib + Sonrotoclax (BGB-11417) in Older (Aged ≥80 Years) and/or Frail Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL). <em>German CLL Study Group</em>. https://clinicaltrials.gov/study/NCT07899398
Vancouver
Anonymous. A Prospective, Open-label, Multicentre Phase-II-trial to Evaluate the Efficacy and Safety of a Fitness-adapted Therapy Approach With Either Continuous Zanubrutinib (BGB-3111) Monotherapy or Time-limited Zanubrutinib + Sonrotoclax (BGB-11417) in Older (Aged ≥80 Years) and/or Frail Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL). German CLL Study Group. 2026.
BibTeX
@misc{anon2026AProsp, title = {A Prospective, Open-label, Multicentre Phase-II-trial to Evaluate the Efficacy and Safety of a Fitness-adapted Therapy Approach With Either Continuous Zanubrutinib (BGB-3111) Monotherapy or Time-limited Zanubrutinib + Sonrotoclax (BGB-11417) in Older (Aged ≥80 Years) and/or Frail Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL)}, author = {Anonymous}, journal = {German CLL Study Group}, year = {2026}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings